Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer

被引：0
|
作者：
Laura Mezquita
Marianne Oulhen
Agathe Aberlenc
Marc Deloger
Mihaela Aldea
Aurélie Honore
Yann Lecluse
Karen Howarth
Luc Friboulet
Benjamin Besse
David Planchard
Françoise Farace
机构：
[1] Gustave Roussy,
[2] Université Paris-Saclay,undefined
[3] Department of Medicine,undefined
[4] Medical Oncology Department,undefined
[5] Hospital Clinic of Barcelona,undefined
[6] Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors,undefined
[7] IDIBAPS,undefined
[8] Gustave Roussy,undefined
[9] Université Paris-Saclay,undefined
[10] “Rare Circulating Cells” Translational Platform,undefined
[11] CNRS UMS3655—INSERM US23 AMMICA,undefined
[12] INSERM,undefined
[13] U981 “Identification of Molecular Predictors and new Targets for Cancer Treatment”,undefined
[14] Gustave Roussy,undefined
[15] Université Paris-Saclay,undefined
[16] Bioinformatics Platform,undefined
[17] CNRS UMS3655—INSERM US23 AMMICA,undefined
[18] Gustave Roussy,undefined
[19] Université Paris-Saclay,undefined
[20] Genomic Platform,undefined
[21] CNRS UMS3655—INSERM US23 AMMICA,undefined
[22] Gustave Roussy,undefined
[23] Université Paris-Saclay,undefined
[24] “Flow cytometry and Imaging” Platform,undefined
[25] CNRS UMS3655—INSERM US23AMMICA,undefined
[26] Inivata Ltd,undefined
[27] Babraham Research Park,undefined
来源：
British Journal of Cancer | 2024年 / 130卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：682 / 693
页数：11
相关论文
共 50 条
  • [1] Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer
    Mezquita, Laura
    Oulhen, Marianne
    Aberlenc, Agathe
    Deloger, Marc
    Aldea, Mihaela
    Honore, Aurelie
    Lecluse, Yann
    Howarth, Karen
    Friboulet, Luc
    Besse, Benjamin
    Planchard, David
    Farace, Francoise
    BRITISH JOURNAL OF CANCER, 2024, 130 (04) : 682 - 693
  • [2] Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non-Small-Cell Lung Cancer
    Rudin, Charles M.
    Hong, Kelvin
    Streit, Michael
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (05) : E41 - E42
  • [3] Resistance mechanisms to BRAF inhibition identified by single circulating tumor cell and cell-free tumor DNA molecular profiling in BRAF-mutant non-small cell lung cancer.
    Mezquita, Laura
    Oulhen, Marianne
    Aberlenc, Agathe
    Deloger, Marc
    Honore, Aurelie
    Garonzi, Marianna
    Buson, Genny
    Forcato, Claudio
    Lecluse, Yann
    Aldea, Mihaela
    NgoCamus, Maud
    Nicotra, Claudio
    Howarth, Karen
    Lacroix, Ludovic
    Friboulet, Luc
    Besse, Benjamin
    Manaresi, Nicolo
    Planchard, David
    Farace, Francoise
    CANCER RESEARCH, 2021, 81 (13)
  • [4] Circulating tumour DNA (ctDNA) analysis depicts mechanisms of resistance and tumour response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC)
    Ortiz-Cuaran, S.
    Mezquita, L.
    Swalduz, A.
    Aldea, M.
    Mazieres, J.
    Jovelet, C.
    Lacroix, L.
    Pradines, A.
    Avrillon, V.
    Ouhatar, C. -MahierAit
    Hoog-Labouret, N.
    Howarth, K.
    Guichou, J-F.
    Morris, C.
    Green, E.
    Perol, M.
    Besse, B.
    Blay, J-Y.
    Saintigny, P.
    Planchard, D.
    ANNALS OF ONCOLOGY, 2019, 30 : 641 - 641
  • [5] Targeting BRAF-Mutant Non-Small Cell Lung Cancer: FromMolecular Profiling to Rationally Designed Therapy
    Baik, Christina S.
    Myall, Nathaniel J.
    Wakelee, Heather A.
    ONCOLOGIST, 2017, 22 (07): : 786 - 796
  • [6] BRAF Mutations in Non-Small-Cell Lung Cancer
    Smit, Egbert
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (11) : 1594 - 1595
  • [7] Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class
    Mendoza, Dexter P.
    Dagogo-Jack, Ibiayi
    Chen, Tianqi
    Padole, Atul
    Shepard, Jo-Anne O.
    Shaw, Alice T.
    Digumarthy, Subba Rao
    LUNG CANCER, 2019, 129 : 80 - 84
  • [8] Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer
    Ortiz-Cuaran, Sandra
    Mezquita, Laura
    Swalduz, Aurelie
    Aldea, Mihalea
    Mazieres, Julien
    Leonce, Camille
    Jovelet, Cecile
    Pradines, Anne
    Avrillon, Virginie
    Flores, Washington R. Chumbi
    Lacroix, Ludovic
    Loriot, Yohann
    Westeel, Virginie
    Ngo-Camus, Maud
    Tissot, Claire
    Raynaud, Christine
    Gervais, Radj
    Brain, Etienne
    Monnet, Isabelle
    Leprieur, Etienne Giroux
    Caramella, Caroline
    Oukhatar, Celine Mahier-Ait
    Hoog-Labouret, Natalie
    de Kievit, Frank
    Howarth, Karen
    Morris, Clive
    Green, Emma
    Friboulet, Luc
    Chabaud, Sylvie
    Guichou, Jean-Francois
    Perol, Maurice
    Besse, Benjamin
    Blay, Jean-Yves
    Saintigny, Pierre
    Planchard, David
    CLINICAL CANCER RESEARCH, 2020, 26 (23) : 6242 - 6253
  • [9] BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors
    Miguel Sanchez-Torres, Jose
    Viteri, Santiago
    Angel Molina, Miguel
    Rosell, Rafael
    TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (03) : 244 - 250
  • [10] The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer
    Zhang, Longyao
    Zheng, Linpeng
    Yang, Qiao
    Sun, Jianguo
    FRONTIERS IN ONCOLOGY, 2022, 12
12345